Outcomes in hepatocellular carcinoma patients undergoing sorafenib treatment: toxicities, cellular oxidative stress, treatment adherence, and quality of life: Erratum

Anticancer Drugs. 2021 Feb 1;32(2):345-364. doi: 10.1097/CAD.0000000000001029.
No abstract available

Publication types

  • Published Erratum